<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01316042</url>
  </required_header>
  <id_info>
    <org_study_id>35865</org_study_id>
    <nct_id>NCT01316042</nct_id>
  </id_info>
  <brief_title>Metformin for the Treatment of Premature Pubarche in Girls</brief_title>
  <official_title>A Double Blind Randomized Controlled 12 Month Trial of Metformin for the Treatment of Premature Pubarche in Girls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the safety and efficacy of metformin in
      lowering serum DHEAS levels in girls with premature pubarche and secondary, to observe
      changes in hormones associated with pubertal development including gonadotropins, sex
      steroids, insulin, adipocytokines, and growth factors.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    poor recruitment at collaborating sites
  </why_stopped>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Serum DHEAS Levels</measure>
    <time_frame>1 year</time_frame>
    <description>Change in DHEAS level was constructed per subject as the 1-year measurement minus the baseline measurement. Only descriptive statistics are provided, statistical tests were not conducted given the extremely small sample size per group.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Premature Pubarche</condition>
  <arm_group>
    <arm_group_label>sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 pills per day for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 212.5mg pill/day for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sugar pill</intervention_name>
    <description>2 pills per day for 12 months</description>
    <arm_group_label>sugar pill</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin, glucophage</intervention_name>
    <description>2 212.5mg pills/day for 12 months</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>metformin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Girls aged 4-10 with pubic hair prior to 8 years of age

          2. Elevated DHEAS level above age normal levels

          3. Informed consent from parents and assent from the girl

        Exclusion Criteria:

          1. Diagnosis of incomplete precocious puberty, peripheral precocious puberty, or evidence
             of any abnormal pituitary, hypothalamic, adrenal, thyroid, and gonadal function other
             than premature secretion of adrenal androgens.

          2. Chronic illness requiring treatment that may interfere with growth and development,
             i.e. chronic steroid use, renal failure, etc.

          3. 21-hydroxylase deficiency or other enzyme deficiency leading to the phenotype of
             congenital adrenal hyperplasia. 21-hydroxylase deficiency will be excluded in all
             patients by a fasting 17-hydroxyprogesterone (17-OHP) level &lt; 2 ng/mL. In the case of
             elevated fasting 17-OHP levels, an ACTH stimulation test will be performed. A 1-hour
             stimulated value &gt; 10 ng/mL will be an exclusion 82. As 21 hydroxylase deficiency is a
             congenital condition, any normal level in the past of 17-hydroxyprogesterone allows
             entry into this study.

          4. Uncorrected thyroid disease (defined as TSH &lt; 0.2 mIU/ML or &gt; 5.5 mIU/mL). A normal
             level within the last year is adequate for entry.

          5. Type I or Type II diabetes (defined as a fasting serum glucose &gt; 125mg/dL on two
             occasions 83), or patients receiving anti-diabetic medications such as insulin,
             thiazolidinediones, acarbose, or sulfonylureas; patients currently receiving metformin
             XR for a diagnosis of Type I or Type II diabetes or for PCOS are also specifically
             excluded.

          6. Liver disease defined as AST or ALT &gt; 2 times normal or total bilirubin &gt; 2.5 mg/dL.

          7. Renal disease defined as BUN &gt; 30 mg/dL or serum creatinine &gt; 1.4 mg/dL.

          8. Significant anemia (Hemoglobin &lt; 10 mg/dL).

          9. History of deep venous thrombosis, pulmonary embolus, or cerebrovascular accident.

         10. Known heart disease (New York Heart Association Class II or higher).

         11. Enrolled simultaneously into other investigative studies that require medications,
             proscribe the study medications, or otherwise prevent compliance with the protocol.
             Patients who anticipate taking longer than a one month break during the protocol
             should not be enrolled.

         12. Concomitant use other medications known to affect reproductive function or metabolism.
             These medications include growth hormone, IGF-1, medroxyprogesterone acetate, oral
             contraceptives, GnRH agonists and antagonists, anti-androgens, gonadotropins,
             anti-obesity drugs, somatostatin, diazoxide, ACE inhibitors, and calcium channel
             blockers. The washout period on all these medications will be three months.

         13. Suspected adrenal or ovarian tumor secreting androgens or other ectopic steroid
             secreting tumor.

         14. Suspected Cushing's syndrome.

         15. Lactose intolerance (the placebo filler is lactose).

         16. Known hypersensitivity to study medication, including ACTH and GnRH, or their
             excipients.

         17. Any concomitant medical condition that in the opinion of the investigator, may expose
             a subject to unacceptable level of safety risk, or that affects subject compliance.

         18. Subjects who anticipate having any surgery associated with restricted intake of fluids
             or radiological studies with contrast dye during the study period.

         19. Any concomitant medical condition that in the opinion of the investigator, may expose
             a subject to unacceptable level of safety risk, or that affects subject compliance.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard S Legro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Riley Hospital for Children, Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh at the University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pennstatehershey.org/obgyn</url>
    <description>departmental website</description>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2011</study_first_submitted>
  <study_first_submitted_qc>March 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2011</study_first_posted>
  <results_first_submitted>April 7, 2016</results_first_submitted>
  <results_first_submitted_qc>April 7, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 12, 2016</results_first_posted>
  <last_update_submitted>April 7, 2016</last_update_submitted>
  <last_update_submitted_qc>April 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Richard S. Legro, M.D.</investigator_full_name>
    <investigator_title>Professor, Obstetrics and Gynecology and Public Health Sciences</investigator_title>
  </responsible_party>
  <keyword>Puberty</keyword>
  <keyword>Hormones</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Puberty, Precocious</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sugar Pill</title>
          <description>2 pills per day for 12 months</description>
        </group>
        <group group_id="P2">
          <title>Metformin</title>
          <description>2 212.5mg pill/day for 12 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sugar Pill</title>
          <description>2 pills per day for 12 months</description>
        </group>
        <group group_id="B2">
          <title>Metformin</title>
          <description>2 212.5mg pill/day for 12 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.5" lower_limit="6" upper_limit="9"/>
                    <measurement group_id="B2" value="6" lower_limit="6" upper_limit="6"/>
                    <measurement group_id="B3" value="6.75" lower_limit="6" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>DHEAS</title>
          <units>ug/dL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177.0" lower_limit="59.0" upper_limit="295.0"/>
                    <measurement group_id="B2" value="67.6" lower_limit="51.0" upper_limit="84.2"/>
                    <measurement group_id="B3" value="122.3" lower_limit="51.0" upper_limit="295.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum DHEAS Levels</title>
        <description>Change in DHEAS level was constructed per subject as the 1-year measurement minus the baseline measurement. Only descriptive statistics are provided, statistical tests were not conducted given the extremely small sample size per group.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill</title>
            <description>2 pills per day for 12 months</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>2 212.5mg pill/day for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum DHEAS Levels</title>
          <description>Change in DHEAS level was constructed per subject as the 1-year measurement minus the baseline measurement. Only descriptive statistics are provided, statistical tests were not conducted given the extremely small sample size per group.</description>
          <units>ug/dL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.25" lower_limit="-11.0" upper_limit="31.5"/>
                    <measurement group_id="O2" value="4.8" lower_limit="4.8" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sugar Pill</title>
          <description>2 pills per day for 12 months</description>
        </group>
        <group group_id="E2">
          <title>Metformin</title>
          <description>2 212.5mg pill/day for 12 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pink eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination of the study due to low recruitment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Richard S. Legro, M.D.</name_or_title>
      <organization>Milton S. Hershey Medical Center</organization>
      <phone>717-531-8478</phone>
      <email>rlegro@hmc.psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

